Latest Content

Learn how psychiatrists lead through change with emotional intelligence, mentorship, and early leadership roles that boost teamwork and patient safety.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

A psychiatrist fights denials for GLP‑1 weight-loss drugs, exposing how high costs and rigid rules deepen obesity care inequities.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Explore the new Psychiatric Times digital issue, featuring articles, multimedia, and interactive learning to sharpen your clinical skills.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

A rare psychiatrist-publisher dies at 97; explore Jason Aronson’s publishing legacy, Jewish studies ties, and free classic psychotherapy downloads.

Explore how AI transforms healthcare by enhancing diagnostics, personalizing treatments, and improving access while addressing significant risks and limitations.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Inside the opioid epidemic: psychiatry and addiction care, MOUD options, and why stigma, policy, and jails still block lifesaving treatment.